Take­da joins forces with small pri­vate biotech for pre­clin­i­cal Alzheimer's re­search

Take­da is wad­ing deep­er in­to Alzheimer’s dis­ease re­search with a new pre­clin­i­cal col­lab­o­ra­tion an­nounced Tues­day.

The com­pa­ny will work with Treven­tis, a lit­tle-known pri­vate biotech from Toron­to, on a small mol­e­cule pro­gram tar­get­ing the tau pro­tein. Treven­tis CEO Christo­pher Bar­den tells End­points News the biotech is still work­ing on se­lect­ing which drug can­di­date to move for­ward and will use Take­da’s help to make that choice. Take­da can then op­tion it in­to fur­ther pre­clin­i­cal, and po­ten­tial­ly clin­i­cal, stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER